Pharma Two B develops clinically differentiated and value-added products, based on approved drugs. The company focuses on Fixed-Dose-combinations of two or more drugs with complementary and synergistic effects, providing high clinical value and shorter regulatory pathways (US 505(b)(2) approach). The company develops products in two therapeutic areas with great unmet needs, Parkinson’s disease and Cancer.
The Company’s leading product, P2B001 was successfully tested in a phase IIb clinical study with 149 parkinson’s disease patients in the US and Israel. The results showed a significant effect of improvement in the subjects condition according to several Parkinson’s disease scales compared to Placebo.
Pharma Two B main investors include Crossroad and JK&B.